Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
September 26 2019 - 8:00AM
Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage
biopharmaceutical company focused on the development of novel
therapeutic compounds to treat disease through the inhibition of
the complement system, today announced that it will present at the
2019 Cantor Global Healthcare Conference on Thursday, October 3,
2019 at 11:15 a.m. ET in New York, NY.
The presentation will be given by Cedric Francois,
M.D., Ph.D., founder and chief executive officer of Apellis, and
will be available via live webcast from the “Events and
Presentations” page of the “Investors and Media” section of the
Company’s website at
http://investors.apellis.com/events-and-presentations. A replay of
the webcast will be available for 90 days following the event.
About ApellisApellis Pharmaceuticals,
Inc. is a clinical-stage biopharmaceutical company focused on
the development of novel therapeutic compounds for the treatment of
a broad range of life-threatening or debilitating autoimmune
diseases based upon complement immunotherapy through the inhibition
of the complement system at the level of C3. Apellis is the first
company to advance chronic therapy with a C3 inhibitor into
clinical trials. For additional information about Apellis and
APL-2, please visit http://www.apellis.com.
Investor Contact:
Alex Kane
akane@w2ogroup.com
212.301.7218 (office)
929.400.2691 (mobile)
Media Contact:
Tracy Vineis
tracy.vineis@apellis.com
617.420.4839 (office)
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Apr 2023 to Apr 2024